About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

378040 studies
in
220 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 06/15/2021.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 06/15/2021.

Efficacy of High Velocity Nasal Insufflation

Clinicaltrials.gov identifier NCT03929055

Recruitment Status Recruiting

First Posted April 26, 2019

Last update posted November 5, 2020

Study Description

Brief summary:

The purpose of this study is to assess the effect of HFNC on esophageal pressure and diaphragmatic function in patients with acute respiratory failure

  • Condition or Disease:Acute Respiratory Failure
    Diaphragmatic Function
    Esophageal Pressure
  • Intervention/Treatment: Device: Physiological assesment
  • Phase: N/A
Detailed Description

In recent years, new devices that deliver totally conditioned gas through a nasal cannula at high flow have emerged as a safe and useful supportive therapy in many clinical situations. High flow nasal cannula (HFNC) supportive therapy is one such technique that exerts its potential benefits through a variety of mechanisms. In the last two decades, HFNC supportive therapy has emerged as a safe, useful therapy in patients with respiratory failure. Several mechanisms are known to contribute to oxygenation improvement and carbon dioxide reduction, which are the main potential benefits of using HFNC therapy. However, the exact contributions of each mechanism have not been conclusively established and these may, in fact, vary from one patient to another. Recently several clinical trials have analyzed the effectiveness of HFNC therapy in different clinical situations and have reported promising results such as the potential to improve clinical outcomes. However, the physiologic mechanisms underlying the clinical benefits of HFNC are still poorly understood in adult patients. Basic clinical monitoring during HFNC therapy demonstrated rapid improvement of oxygenation and reduction of dyspnea in comparison to a standard facial mask. Findings in other populations indicate that advanced respiratory monitoring might demonstrate other specific physiologic effects such as the reduction in inspiratory effort and increment in lung volume that may prevent respiratory muscle exhaustion and lower the tidal volume/end expiratory lung volume (EELV) ratio. Moreover, It has been hypothesized that the continuous administration of a very high flow of gas flushes the carbon dioxide (CO2) out of the upper respiratory airway, avoiding the re-inhalation of the previous exhaled gas. A randomized, crossover, experimental study with neonatal piglets with lung injury treated with continuous positive airway pressure (CPAP; minimal leak) or a HFNC with a high or low degree of leak around the nasal prongs showed that under both HFNC leak conditions PaCO2 decreased and oxygen arterial pressure (PaO2) increased with increasing flow. This effect of nasopharyngeal dead space washout was associated more with increases in flow rates than with increases in pressure. Thus, compared with the masks used with conventional oxygen delivery devices, nasal prongs reduce dead space. Additionally, high velocity flows likely reduce inspiratory resistance and allow the patient to breathe from their dead space, rather than through it. This is how high velocity Nasal Insufflation helps reduce work of breathing, respiratory rate and assists in increasing alveolar ventilation efficiency. The relative contribution of the patient's effort during assisted breathing is difficult to measure in clinical conditions, and the diaphragm, the major muscle of inspiratory function, is inaccessible to direct clinical assessment. Several methods have been used in the research setting to assess diaphragmatic contractile activity. Bedside ultrasonography, which is already crucial in several aspects of critically illness, has been recently proposed as a simple, non-invasive method of quantification of diaphragmatic contractile activity . Ultrasound can be used to determine diaphragm excursion which may help to identify patients with diaphragm dysfunction Ultrasonographic examination can also allow for the direct visualization of the diaphragm thickness in its zone of apposition. Thickening during active breathing has been proposed to reflect the magnitude of diaphragmatic effort, similarly to an ejection fraction of the heart. In spontaneously breathing patients, thickness fraction was shown to be positively related to tidal volume and thickness measurements during spontaneous breathing may be influenced by lung volume in a non-linear relationship, and diaphragmatic thickening was shown to be more pronounced above 50% of vital capacity. It seems reasonable to expect that the high flow nasal cannula may modify the thickness or diaphragm thickening and its excursion depend on the level of positive end expiration pressure generated. On the other hand, it could also happen that with a relevant increase in tidal volume the diaphragmatic excursion may remain constant. The most likely explanation is that a higher portion of the tidal volume (VT) is distributed to the non-dependent lung region due to better compliance of this area, as recently shown with electrical impedance tomography analysis. Another possible explanation is that patients' respiratory muscles could be over-assisted and the diaphragm may be passively displaced downward by simply improving gas exchange efficacy. The aim of the present study is to compare the HFNC, Helmet continues positive airway pressure (CPAP) and venturi mask on the inspiratory effort, respiratory rate, gas exchange, level of dyspnea and diaphragmatic function evaluated by US in a group of patients with acute respiratory failure (ARF). Inclusion and exclusion criteria The study has been submitted to our local ethics committee and patients will receive their written informed consent. All consecutive patients with acute respiratory failure presenting as respiratory rate higher than 25-30; Pao2 / oxygen inspiratory fraction (FiO2) ratio less than 300 supported with venturi mask at 30% Fio2. Patients will be exclude if there will be present one of the following conditions: PaO2/FiO2 less than 100; hemodynamic instability (mean arterial pressure lower than 60 mmHg after fluid challenge) and impossibility to insert the esophageal monitoring. Sample size calculation is based on the results of the study by Mauri, in which the application of HFNC at a similar flow rate to patients suffering from acute hypoxemic respiratory failure determined a reduction in esophageal pressure swing from 9.4+-4.1 to 7.9+-3.0. If the investigators hypothesize that a similar effect size is present in our patient population, a sample size of 25 patients will be necessary to achieve a level of significance of 0.05, with a 0.8 power, for a repeated-measures study design. Normally distributed variables are expressed as mean ± standard deviations and were analysed by a paired t-test. Non-normally distributed variables are expressed as medians and were compared by Wilcoxon's signed rank test. Correlations were analysed by Pearson's coefficient. A level of p<0.05 (two-tailed) was considered statistically significant. Experimental settings and Measurements A cross over study. Patients will enter in the three study phases with the same set clinical FiO2 for 20 minutes: standard Venturi oxygen mask with FiO2 regulated to achieve 90-04% of oxygen saturation (SpO2) with a flow rate of 35-40 Litters/minute (L/m); high velocity nasal insufflation (Precision Flow) with optimized gas flow; Helmet CPAP with positive end expiatory pressure (PEEP) set to reach the same esophageal swing obtained with HFNC. Using a small-bore nasal cannula the study will start with a flow rate set to 35 L/min, with a starting temperature between 35°C and 37°C and FIO2 at 1.0. Adjustments in flow (within the range of 25 L/min to 40 L/min) and temperature (typically between 35°C to 37°C) are made to alleviate respiratory distress and optimize comfort; FIO2 was titrated to maintain SpO2 at 90-94%. At enrolment, the investigators will collect the patients' main demographics and clinical data. An esophageal balloon catheter will be placed in the esophagus, as demonstrated by the appearance of cardiac artefacts and appropriate negative swings of pressure tracings during inspiration. Esophageal pressure waveforms will be continuously recorded by a dedicated data acquisition system throughout the study. At each steps ultrasonography of the diaphragm will be performed using an ultrasound machine (GE Healthcare) equipped with a high-resolution 10-megahertz (MHz) linear probe and a 7.5-MHz convex phased-array probe. Images will be recorded for subsequent computer- assisted quantitative analysis performed by a trained investigator. The convex probe will be placed below the right costal margin along the mid-clavicular line, so that the ultrasound beam are perpendicular to the posterior third of the corresponding hemi-diaphragm, as previously described. Patients will be scanned along the long axis of the intercostal spaces, with the liver serving as an acoustic window. M-mode will then be used to display diaphragm excursion. Diaphragm thickness (DT) will be assessed in the zone of apposition of the diaphragm to the rib cage. The inferior border of the costophrenic sinus will be identified as the zone of transition from the artifactual representation of normal lung to the visualization of the diaphragm and liver. In this area, the diaphragm is observed as a three-layered structure: a non-echogenic central layer bordered by two echogenic layers, the peritoneum and the diaphragmatic pleurae.

Study Design
  • Study Type: Interventional
  • Estimated Enrollment: 25 participants
  • Allocation: Non-Randomized
  • Intervention Model: Crossover Assignment
  • Masking: None (Open Label) ()
  • Primary Purpose: Treatment
  • Official Title: Efficacy of High Velocity Nasal Insufflation Compared With Venturi Mask and Helmet CPAP in Acute Respiratory Failure
  • Actual Study Start Date: January 2018
  • Estimated Primary Completion Date: June 2021
  • Estimated Study Completion Date: June 2021
Arms and interventions
Arm Intervention/treatment
Active Comparator: CPAP
Helmet CPAP is set to obtain the same esophageal pressure variation during HFNC step
Device: Physiological assesment
Arterial blood gas analysis. esophageal pressure variation during inspiration and expiration Arterial blood pressure, central venous pressure (CVP), heart rate. diaphragmatic contraction detected by ultrasound
Active Comparator: HFNC
HFNC is set to obtain the same oxygen fraction of venturi mask and flow of 40l/min
Device: Physiological assesment
Arterial blood gas analysis. esophageal pressure variation during inspiration and expiration Arterial blood pressure, central venous pressure (CVP), heart rate. diaphragmatic contraction detected by ultrasound
Active Comparator: venturi mask
oxygen is delivered by venturi mask to achieve peripheral oxygen saturation of al least 92%
Device: Physiological assesment
Arterial blood gas analysis. esophageal pressure variation during inspiration and expiration Arterial blood pressure, central venous pressure (CVP), heart rate. diaphragmatic contraction detected by ultrasound
Outcome Measures
  • Primary Outcome Measures: 1. effects of HFNC on esophageal pressure variation [ Time Frame: one day ]
    the esophageal pressure will be measure using an esophageal ballon catheter. A decrease in esophageal pressure variation during HFNC treatment compared with CPAP
  • Secondary Outcome Measures: 1. effect of HFNC on diaphragmatic function [ Time Frame: one day ]
    the diaphragmatic function will be detected using the ultrasound. An improvement in diaphragmatic contractility function as detected by the increase in its thickness ratio is expected during HFNC treatment compared with CPAP
Eligibility Criteria
  • Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
  • Sexes Eligible for Study: All
  • Accepts Healthy Volunteers: No
Criteria

Inclusion Criteria:

- patient with acute respiratory failure, not intubated, who require non invasive
mechanical ventilation

Exclusion Criteria:

- patients in which it is not possible to place the esophageal catheter or it is not
possible to detect the diaphragm by ultrasound or it is not possible to apply the
nasal cannula device

Contacts and Locations
Contacts
Locations

Italy
ASST-Santi Paolo e Carlo, San Paolo Hospital
Milan

Sponsors and Collaborators

University of Milan

More Information
  • Responsible Party: University of Milan
  • ClinicalTrials.gov Identifier: NCT03929055 History of Changes
  • Other Study ID Numbers: HFNC
  • First Posted: April 26, 2019 Key Record Dates
  • Last Update Posted: November 5, 2020
  • Last Verified: November 2020
  • Studies a U.S. FDA-regulated Drug Product: No
  • Studies a U.S. FDA-regulated Device Product: No
  • Additional relevant MeSH terms: Respiratory Distress Syndrome, Adult Respiratory Insufficiency